ALSFRS-R

Overview

Journal Amyotroph Lateral Scler Other Motor Neuron Disord

Specialty Neurology

Date 2004 Oct 30

PMID 15512883

Citations 34

Authors

Paul H Gordon

Robert G Miller

Dan H Moore

Affiliations

Soon will be listed here.

Abstract

The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimizes dropout, reduces cost, and correlates with survival. Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function.

Citing Articles

Reliability and consistency of the Japanese version of the Primary Lateral Sclerosis Functional Rating Scale.

Yanagihashi M, Hirayama T, Shibukawa M, Nagasawa J, Fujita K, Izumi Y BMC Neurol. 2024; 24(1):282.

PMID: 39138414 PMC: 11320838. DOI: 10.1186/s12883-024-03729-6.

Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data.

Cai R, Yang J, Wu L, Liu Y, Wang X, Zheng Q Orphanet J Rare Dis. 2024; 19(1):40.

PMID: 38308282 PMC: 10837960. DOI: 10.1186/s13023-024-03057-5.

Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.

Mitsumoto H, Cheung K, Oskarsson B, Andrews H, Jang G, Andrews J Trials. 2023; 24(1):449.

PMID: 37430314 PMC: 10332004. DOI: 10.1186/s13063-023-07424-8.

Potential role of vitamin D levels in amyotrophic lateral sclerosis cognitive impairment.

De Marchi F, Saraceno M, Sarnelli M, Virgilio E, Cantello R, Mazzini L Neurol Sci. 2023; 44(8):2795-2802.

PMID: 36949299 PMC: 10345066. DOI: 10.1007/s10072-023-06751-7.

A meta-analysis of post-exercise outcomes in people with amyotrophic lateral sclerosis.

Donohue C, Carnaby G, Reilly M, Colquhoun R, Lacomis D, Garand K eNeurologicalSci. 2023; 31:100452.

PMID: 36875937 PMC: 9982645. DOI: 10.1016/j.ensci.2023.100452.